Univariate and multivariate analysis of factors predictive of vasculitis relapse in treated patients
| Variables | HR (95% CI) | P values |
| Univariate analysis | ||
| Age (years) | 1.00 (0.98 to 1.02) | 0.984 |
| Male (vs female) | 1.00 (0.59 to 1.68) | 0.997 |
| GPA (vs MPA or renal-limited vasculitis) | 2.08 (1.07 to 4.03) | 0.030 |
| PR3-ANCA (vs MPO-ANCA or no ANCA) | 2.18 (1.18 to 4.00) | 0.012 |
| Serum creatinine >2.27 mg/dL | 0.58 (0.30 to 1.10) | 0.093 |
| Ear, nose and throat involvement | 1.59 (0.83 to 3.02) | 0.161 |
| Pulmonary involvement | 1.04 (0.61 to 1.76) | 0.884 |
| Cardiovascular involvement | 1.10 (0.60 to 2.00) | 0.764 |
| Induction to remission ANCA evolution (persistence vs disappearance) | 1.09 (0.65 to 1.82) | 0.756 |
| Multivariate analysis | ||
| PR3-ANCA (vs MPO-ANCA or no ANCA) | 2.04 (1.06 to 3.91) | 0.032 |
| Serum creatinine >2.27 mg/dL | 0.58 (0.31 to 1.11) | 0.100 |
| Ear, nose and throat involvement | 1.18 (0.59 to 2.35) | 0.634 |
| Arm (AZA vs RTX) | 2.72 (1.55 to 4.76) | <0.001 |
ANCA, antineutrophil cytoplasmic antibodies; AZA, azathioprine; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO, myeloperoxidase; PR3, antiproteinase 3; RTX, rituximab.